The Pharmacy Times® Cardiovascular Health resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
The Clinical Performance and Quality Measures included 6 performance measures, 6 process quality measures, and a new category of 10 structural quality measures for adults with high blood pressure.
Sacubitiril/Valsartan Combination Shows Reduction in Hospitalizations in Women with Diastolic Heart Failure
Certain subgroups may see a greater reduction in heart failure hospitalizations and cardiovascular death with the combination of sacubitril and valsartan.
Top news of the day from across the health care landscape.
An analysis presented at the American Heart Association Annual Scientific Sessions showed that evolocumab (Repatha, Amgen) lowered the risk of cardiovascular events in patients who have recently had a heart attack.
cvMOBIUS will examine lipid management and the effectiveness of evolocumab (Repatha, Amgen) on cardiovascular outcomes.
Study Reveals Cost-Effectiveness Strategy of 2017 American Heart Association Guidelines on Hypertension
Implementing more aggressive treatment plans from the American Heart Association’s 2017 guide were seen as more cost-effective over 10 years.
The prevalence of the issue in the United States ranges from 2.7 million to 6.1 million, and this number is expected to increase to 12.1 million by 2030.
Study results have shown that a regimen of once-daily edoxaban (Lixiana, Daiichi Sankyo) combined with a P2Y12 inhibitor is noninferior to the current recommended treatment for patients with atrial fibrillation following successful percutaneous coronary intervention, and may result in less bleeding.
The PHARM-CHF trial investigated whether regularly seeing a pharmacist improves adherence to heart failure medications.
Transthyretin amyloid cardiomyopathy is a rare and fatal disease for which there are no previously approved treatments.
Top news of the day from across the health care industry.
As a result of the agreement, Teva is licensed to launch a generic version of liraglutide (Victoza, Novo Nordisk) as of December 22, 2023.